Latest news
JBIO: Advancing three antibody therapies for autoimmune diseases with strong clinical and financial position - TradingViewTradingView · Mon, 10 Aug 2026 11:44:06 GMTJade Biosciences reports Q2 net loss $55.8M, cash $461.2M; advances JADE101 to Phase 2/3 - TradingViewTradingView · Mon, 10 Aug 2026 11:23:01 GMTJBIO: Strong pipeline progress and robust cash position support continued clinical advancement into 2028 - TradingViewTradingView · Mon, 10 Aug 2026 11:16:12 GMT